載入中
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
收盤時
US$14.46
−US$0.45 · -3.02%
盤後
US$14.46
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
日內區間
目前US$14.46
52週區間
目前US$14.46
盤中時間採用ET。市場資料可能有所延遲。
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
日內區間
目前US$14.46
52週區間
目前US$14.46
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1084.4萬 USD | — | 1萬 USD | 7.5萬 USD | 115.98萬 USD |
| 毛利 | 1084.4萬 USD | — | 1萬 USD | 7.5萬 USD | 115.98萬 USD |
| 研究與開發 | 1.38億 USD | 2806.05萬 USD | 2007.17萬 USD | 2839.09萬 USD | 4749.16萬 USD |
| 銷售、一般及管理費用 | 2539萬 USD | 1632.46萬 USD | 1921.3萬 USD | 1908.7萬 USD | 1711.54萬 USD |
| 營業費用 | 1.63億 USD | 4989.75萬 USD | 3928.53萬 USD | 4747.83萬 USD | 6460.7萬 USD |
| 利息收入 | 287.5萬 USD | 100.12萬 USD | 237.59萬 USD | 71.45萬 USD | 1.98萬 USD |
| 利息支出 | 218.5萬 USD | 85.2萬 USD | — | — | — |
| 折舊和攤銷 | 8.4萬 USD | 3.52萬 USD | 15.33萬 USD | 20.71萬 USD | 26.46萬 USD |
| 營業利益 | −1.53億 USD | −4989.75萬 USD | −3927.53萬 USD | −4740.33萬 USD | −6344.72萬 USD |
| 淨利 | −1.54億 USD | −4852.34萬 USD | −3689.94萬 USD | −4668.88萬 USD | −6342.74萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$36.00
上漲空間 148.96%| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2023年1月13日 | US$0.24Quarterly | — | — |
股息 | 2022年9月21日 | US$1.43Annual | — | — |
除息 2023年1月13日
US$0.24
Quarterly
除息 2022年9月21日
US$1.43
Annual
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1505.03萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1109.8萬0.01%787.4億 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI488.1萬0.05%98.74億 USD0.35%US$151.4-1.54%
iShares Russell 2000 Growth ETFIWO398.71萬0.03%139.17億 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO205.74萬0.01%180億 USD0.06%US$112.27-0.35%
Vanguard Extended Market ETFVXF139.11萬0.00%954億 USD0.05%US$233.52-0.63%
iShares Micro-Cap ETFIWC137.08萬0.10%13.17億 USD0.60%US$181.66-0.73%
Vanguard Health Care ETFVHT103.77萬0.00%220億 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
